Crinetics Pharmaceuticals
Novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 160.9x EV/Revenue -13.8x EV/EBITDA | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | $575m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 339 % | (15 %) | (74 %) | 454 % | 693 % | 282 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (9991 %) | (3544 %) | (5520 %) | (32345 %) | (8281 %) | (1089 %) | (249 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (9985 %) | (3460 %) | (5346 %) | (28721 %) | (7834 %) | (1109 %) | (234 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 7816 % | 2749 % | 4200 % | 23114 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company specializing in the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company operates in the biopharmaceutical market, targeting conditions that have limited treatment options. Crinetics serves patients with rare endocrine disorders, such as acromegaly, by developing innovative oral treatments like CRN00808, which is currently in Phase 2 clinical trials. The business model focuses on advancing drug candidates through clinical trials and obtaining regulatory approvals to bring these therapies to market. Revenue is generated through the commercialization of approved drugs and potential partnerships or licensing agreements with larger pharmaceutical companies.
Keywords: endocrine diseases, rare disorders, novel therapeutics, clinical trials, drug discovery, acromegaly, oral treatments, biopharmaceutical, GPCRs, commercialization.
